OR YEHUDA, Israel, Sept. 16, 2016 /PRNewswire/ -- Valtech Cardio, Ltd., (Valtech), an innovator in the field of device development for mitral and tricuspid valve repair and replacement, today announced that it will present the first-in-man data for its Cardioband Tricuspid (TR) system at PCR London Valves 2016, held September 18-20 at ExCel London. In addition, updated two-year follow-up results of the multi-center Cardioband Mitral study will be presented at the meeting.
"We look forward to sharing details of several Cardioband TR procedures performed since June 2016. Cardioband TR offers the advantages of the mitral platform with its proven durability and effectiveness, providing Tricuspid patients with an innovative option for repair of their valve," said Valtech Founder and CEO Amir Gross. "We're also pleased to be sharing an update on Cardioband Mitral procedure outcomes. Since its limited release, outcomes from dozens of active commercial and study sites across Europe have shown that the Cardioband Mitral procedure is structured, straightforward and reproducible – encouraging news that we are excited to share with the medical community."
"I am pleased to share my first experience with Cardioband Tricuspid, which shows that it is feasible to perform a successful trans venous surgical like annuloplasty procedure for the treatment of TR," said Francesco Maisano, M.D, chairman and professor of cardiovascular surgery at The University Hospital of Zurich who successfully performed the first implantation of Cardioband Tricuspid. "The device has the potential to reproduce surgical standards, although our experience is still limited at the moment."
A Valtech symposium titled, "Cardioband: Clinical Reality for Mitral and Tricuspid Valve Repair," will be led by Eberhard Grube, M.D., Ph.D. (University of Bonn, Germany) and Karl-Heinz Kuck, MD (Asklepios Klinic St. Georg, Hamburg, Germany) Tuesday September 20th in the Main Arena. Panelists will discuss how they are successfully using Cardioband to apply the surgical gold standard in a transfemoral approach.
An accepted talk, "Direct annuloplasty - Cardioband in tricuspid regurgitation", will be presented by Prof. K.H. Kuck (Asklepios Klinic St. Georg, Hamburg, Germany) as part of the "innovation in percutaneous tricuspid valve intervention" session held Sunday September 18th from (3:40pm to 4:35pm, Room 5)
An accepted abstract, "One Year Follow-up Results of Mitral Valve Transcatheter Annuloplasty System for Mitral Reconstruction Multicentre Trial," will be presented by Prof. R. S. von Bardeleben (University of medicine Mainz Germany) as part of the "Mitral and Tricuspid Valve Interventions" session held Monday September 19th from (9:30 AM to 10:30 AM, Room 4).
An additional accepted abstract, "Cardioband implantation to treat recurrent mitral regurgitation after MitraClip therapy," will be presented by Dr. M. Taramasso (University Hospital of Zurich) as part of the "Percutaneous mitral therapies" session held Tuesday September 20th from (11:00 AM to 12:30 PM, Room 5).
In addition to these presentations, attendees of PCR London Valves 2016 can visit Valtech at Booth #7 and learn about Cardioband procedures at the Training Village.
Cardioband received CE Mark certification in September 2015 after demonstrating safety and efficacy in a clinical trial among patients with functional mitral regurgitation. Cardioband permits physicians to repair the mitral valve in a first-line setting while preserving the option to perform future percutaneous or surgical valve repair and/or replacement.
Cardioband combines a reconstruction implant, similar to surgical annuloplasty devices, with a transfemoral, transseptal delivery system. Connection of the implant to the mitral annulus is sutureless, using specially designed anchors. Reshaping of the mitral annulus to eliminate FMR is done under physiological conditions and echocardiographic guidance for optimal results.
Cardioband TR is designed to enable physicians to reconstruct the tricuspid valve using the same technique and implant as Cardioband mitral valve repair technology. A first-in-man CE study in Europe is now recruiting.
About Valtech Cardio, Ltd.
Valtech Cardio, Ltd., founded in 2005, is a privately held valvular focused company specializing in the development of devices for mitral and tricuspid valve repair and replacement. Valtech has over 150 patents and patent applications. The company, comprised of multidisciplinary development teams, works in close collaboration with world-renowned heart specialists to provide the best possible therapy for mitral and Tricuspid patients. Valtech is headquartered in Boston, MA with R&D facility in Or Yehuda, Israel. For more information, visit the company's website: www.valtechcardio.com.
Pascale Communications, LLC
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/valtech-cardio-presents-cardioband-tricuspid-successful-first-in-man-cases-and-2-year-cardioband-mitral-data-at-pcr-london-valves-2016-300327369.html
SOURCE Valtech Cardio Ltd